A Amgen
| Market Cap | $187.56B |
| P/E Ratio | 24.45 |
| Forward P/E | 14.94 |
| Dividend Yield | 2.90% |
| Beta | 0.47 |
| 52W Range | $254.30 - $388.16 |
| # Hedge Funds | 5 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Hedge Fund Ownership
| Investor 5 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| David Katz Matrix Asset Advisors | 3.05% | $33.89M | 103,549 | Reduce 2.52% |
| Torray Funds Torray Investment Partners | 3.03% | $21.16M | 64,647 | Reduce 10.87% |
| FPA Queens Road Small Cap Value Fund Bragg Financial Advisors | 0.55% | $16.77M | 51,233 | Reduce 0.39% |
| Mairs & Power Growth Fund Mairs & Power Inc | 0.02% | $1.81M | 5,524 | Reduce 2.52% |
| Dodge & Cox Dodge & Cox | 0.00% | $4.38M | 13,367 | — |
Insider Trading
| Insider Name of the company insider who made the trade 9 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Santos EstebanEVP, Operations | Sale | 24,291 | $379.12 | $9.21M | 26 Feb 2026 | 02 Mar 2026 |
| Santos EstebanEVP, Operations | Sale | 30,501 | $379.12 | $11.56M | 26 Feb 2026 | 02 Mar 2026 |
| Busch Matthew C.VP, Finance & CAO | Sale | 1,000 | $375.79 | $375.79K | 19 Feb 2026 | 20 Feb 2026 |
| Grygiel Nancy A.SVP & CCO | Sale | 1,639 | $337.26 | $552.77K | 20 Nov 2025 | 21 Nov 2025 |
| Grygiel Nancy A.SVP & CCO | Sale | 1,500 | $337.26 | $505.89K | 20 Nov 2025 | 21 Nov 2025 |
| Nancy A. GrygielSVP & CCO | Sale | 1,639 | $337.26 | $552.77K | 20 Nov 2025 | 21 Nov 2025 |
| Nancy A. GrygielSVP & CCO | Sale | 1,500 | $337.26 | $505.89K | 20 Nov 2025 | 21 Nov 2025 |
| Khosla RachnaSVP, Business Development | Sale | 890 | $336.24 | $299.26K | 12 Nov 2025 | 13 Nov 2025 |
| Gordon MurdoEVP, Global Commercial Ops | Sale | 6,879 | $336.83 | $2.32M | 12 Nov 2025 | 13 Nov 2025 |
Frequently Asked Questions
What is AMGN stock price today?
Amgen (AMGN) is currently trading at $347.94. The stock has a 52-week range of $254.30 to $388.16 and a market capitalization of $187.56B.
Is AMGN a good stock to buy in 2026?
Amgen has a P/E ratio of 24.5 (forward P/E: 14.9), a dividend yield of 2.90%, and 1-year performance of +15.8%. 5 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling AMGN stock?
There have been 9 insider transactions for AMGN in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has AMGN stock performed over the past year?
Amgen (AMGN) has returned +15.8% over the past 12 months. The stock traded between $254.30 and $388.16 during this period, and is currently at $347.94.
Which hedge funds own AMGN (Amgen)?
5 tracked hedge funds currently hold AMGN in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is AMGN's market cap and valuation?
Amgen (AMGN) has a market capitalization of $187.56B. The trailing P/E ratio is 24.5 and forward P/E is 14.9. The stock is classified in the Healthcare sector.
What is AMGN's revenue and profitability?
Amgen reported revenue of $36.75B with net income of $7.71B and a profit margin of 0.21%. The stock has a beta of 0.47.
What sector is AMGN in and who are its biggest institutional holders?
Amgen (AMGN) operates in the Healthcare sector. It is held by 5 tracked hedge funds. See the ownership table above for the complete list.